Cabaletta Bio Inc (CABA)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$1.58+4.28%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put CABA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Manage and reduce operating expenses: Comparison needs review.
View ThesisThis stock is volatile — it swings about 3% on a typical day and fell roughly 67% in its worst 12-month stretch.
View RiskCABA’s central case rests on managing costs and funding operations into mid-2027. The company was unprofitable over the past year, with high risk. Its latest quarter beat earnings estimates by 8.1%, though revenue growth data is absent. The desk has no valuation multiple or priced-in expectations for CABA. So the price-versus-growth case cannot be defined from this desk. Our model puts the next-quarter miss probability at 38.0%. The operating-cost pillar needs review, so its status is unverified. Our standing thesis is on watch; this read is provisional.
Trailing returns as of 2026-10-29. CABA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 10 analysts currently covering CABA (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare CABA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CABA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put CABA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Sell-off raises concerns about maintaining financial resources.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Advances: Maintain financial resources to fund operations into mid-2027
Increases financial resources to fund operations into mid-2027.
Advances: Expand clinical development of rese-cel
Positive trial progress supports clinical development expansion.
Advances: Expand clinical development of rese-cel
Commercial launch plans align with growth objectives.
Advances: Expand clinical development of rese-cel
Positive data supports clinical development growth.